Contineum Therapeutics, Inc. (CTNM) intrinsic value & 10-year financials
Contineum Therapeutics, Inc. (CTNM) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $7.08
- Market cap
- $196.1M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -53.3%
- Free cash flow (FY2025)
- -$55.5M
CTNM 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$60.0M | -$2.17 | -$55.5M | — | -36.6% |
| FY2024 | $0 | -$42.3M | -$2.18 | -$33.4M | — | -104.3% |
| FY2023 | $50.0M | $22.7M | $0.08 | $18.9M | 32.2% | -18.9% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Contineum Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Contineum Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -53.3% ROIC.
Contineum Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Contineum Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.